The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Semaglutide is the active ingredient in Wegovy It is also the main component of Ozempic Semaglutide is known to increase the risk of hair loss Semaglutide, the main ingredient in Ozempic and ...

The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a research letter published ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Oral semaglutide reduced risk for cardiovascular ... We must make sure this information is disseminated to physicians of all specialties, namely primary care physicians, nephrologists and ...

ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...